Market Overview

UPDATE: Credit Suisse Initiates Immunogen at Neutral on Valuation

Share:
Related IMGN
Why Cowen & Co Likes Celldex Therapeutics Following Its FDA 'Breakthrough'
Here's Why Oppenheimer Upgraded ImmunoGen To Outperform

Credit Suisse initiated coverage on Immunogen (NASDAQ: IMGN) with a Neutral rating and a $12 price target.

Credit Suisse noted, "We like IMGN for its expected steady cash flow from T-DM1 royalties, its antibody-drug conjugation (ADC) technology, and potential upside from a deep pipeline. However, upside to valuation requires additional drivers for which visibility is currently low."

Immunogen closed at $11.65 on Monday.

Latest Ratings for IMGN

DateFirmActionFromTo
Feb 2015OppenheimerUpgradesMarket PerformOutperform
Dec 2014JP MorganMaintainsNeutral
Dec 2014Leerink Swann

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (IMGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content